Metagenomi Therapeutics

Metagenomi Therapeutics

Biotechnology
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

$29.6M

Market Cap • 10/16/2026

2016

(10 years)

Founded

2024

(2 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,3

P/S

2,2

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

3

EPS

—

Market Cap

Market Cap

29,6M

EV

-53,3M

EV/Revenue

-3,9

EV/EBITDA

0,6

EV/EBIT

0,5

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,6%

Total Yield

-0,6%

Payout

0%

Retained Earnings

-361,4M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

653,3%

Capex/Revenue

2,3%

Capex/D&A

6%

Capex/OCF

-0,4%

SBC/OCF

—

% PPE

24%

% Goodwill

0%

ROE

—

ROIC

—

Leverage

N.D./EBITDA

0,9

Debt/Equity

0%

Current Ratio

4,5

Quick Ratio

4,4

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium